Abstract
Post Kala-Azar Dermal Leishmaniasis (PKDL) is a chronic dermal manifestation which appears in a small proportion of cases following cure from visceral leishmaniasis (VL) episode, and occasionally in patients with no history of VL. The global prevalence of PKDL is not well studied and the available data are based only on estimates. As per the available reports, the incidence of PKDL varies considerably within endemic countries. PKDL diagnosis remains a challenge more because serology does not have much relevance while parasitological and molecular diagnostic tests show either low sensitivity or are difficult to decentralize in the field. The available treatment options are costly, lengthy and frequently toxic. It is believed that PKDL has a multi-factorial and complex origin combining host and parasite factors and perhaps the treatment rendered in VL treatment. PKDL patients harbor Leishmania parasites in the skin, therefore, are considered a durable reservoir of infection that may propagate VL transmission, especially during inter-epidemic periods. Hence, PKDL poses a serious threat to the success of VL elimination program in South Asia and calls for combined and coordinated efforts towards its surveillance and management in India , Nepal , and Bangladesh . In a nutshell, containing PKDL is a must for sustainable elimination of VL from South Asia where VL transmission is anthroponotic .
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
World Health Organization. Post-kala-azar dermal leishmaniasis: a manual for case management and control. Rep. a WHO consulative Meet. 2012:2–3.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111–26. doi:10.1128/CMR.19.1.111-126.2006.
Kumar D, Ramesh V, Verma S, Ramam M, Salotra P. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann Trop Med Parasitol. 2009;103(8):727–30. doi:10.1179/000349809X12554106963438.
Pandey K, Das VNR, Singh D, et al. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J Clin Microbiol. 2012;50(4):1478–9. doi:10.1128/JCM.05966-11.
Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE. Report of the post kala-azar dermal leishmaniasis (PKDL) consortium meeting, New Delhi, India, 27–29 June 2012. Parasit Vectors. 2013;6(1):196. doi:10.1186/1756-3305-6-196.
Rahman KM, Islam S, Rahman MW, et al. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis. 2010;50(1):73–6. doi:10.1086/648727.
Mondal D, Nasrin KN, Huda MM, et al. Enhanced case detection and improved diagnosis of PKDL in a kala-azar-endemic area of Bangladesh. PLoS Negl Trop Dis. 2010;4(10):e832. doi:10.1371/journal.pntd.0000832.
Islam S, Kenah E, Bhuiyan MAA, et al. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh. Am J Trop Med Hyg. 2013;89(2):345–53. doi:10.4269/ajtmh.12-0711.
Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol. 1995;34(2):85–91.
Singh RP, Picado A, Alam S, et al. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Trop Med Int Heal. 2012;17(11):1345–8. doi:10.1111/j.1365-3156.2012.03067.x.
Uranw S, Ostyn B, Rijal A, et al. Post-kala-azar dermal leishmaniasis in nepal: a retrospective cohort study (2000–2010). PLoS Negl Trop Dis. 2011;5(12):e1433. doi:10.1371/journal.pntd.0001433.
Singh RP. Observation on dermal leishmanoid in Bihar. Indian J Dermatol. 1968;13(3):59–63.
Ramesh V, Singh N. A clinical and histopathological study of macular type of post-kala-azar dermal leishmaniasis. Trop Doct. 1999;29(4):205–7.
Ramesh V, Ramam M, Singh R, Salotra P. Hypopigmented post-kala-azar dermal leishmaniasis. Int J Dermatol. 2008;47(4):414–6. doi:10.1111/j.1365-4632.2008.03621.x.
Saha S, Mazumdar T, Anam K, et al. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis. J Clin Microbiol. 2005;43(3):1269–77. doi:10.1128/JCM.43.3.1269-1277.2005.
Musa AM, Khalil EAG, Raheem MA, et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol. 2002;96(8):765–72. doi:10.1179/000349802125002211.
Zijlstra EE, Musa AM, Khalil EAG. el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.
Ismail A, Khalil EAG, Musa AM, et al. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role? Med Hypotheses. 2006;66(5):993–9. doi:10.1016/j.mehy.2005.03.035.
El Hassan AM, Khalil EA, el Sheikh EA, Zijlstra EE, Osman A, Ibrahim ME. Post kala-azar ocular leishmaniasis. Trans R Soc Trop Med Hyg. 1998;92(2):177–9.
Rihl M, Stoll M, Ulbricht K, Bange F-C, Schmidt R-E. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect. 2006;53(1):e25–7. doi:10.1016/j.jinf.2005.09.015.
Stark D, Pett S, Marriott D, Harkness J. Post-kala-azar dermal leishmaniasis due to leishmania infantum in a human immunodeficiency virus type 1-infected patient. J Clin Microbiol. 2006;44(3):1178–80. doi:10.1128/JCM.44.3.1178-1180.2006.
Antinori S, Longhi E, Bestetti G, et al. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol. 2007;157(5):1032–6. doi:10.1111/j.1365-2133.2007.08157.x.
Singh A, Ramesh V, Ramam M. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients. Indian J Dermatol Venereol Leprol. 2015;81(1):29–34. doi:10.4103/0378-6323.148562.
Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res. 2006;123(3):295–310.
Salotra P, Sreenivas G, Nasim AA, Subba Raju BV, Ramesh V. Evaluation of enzyme-linked immunosorbent assay for diagnosis of post-kala-azar dermal leishmaniasis with crude or recombinant k39 antigen. Clin Diagn Lab Immunol. 2002;9(2):370–3.
Riera C, Fisa R, Lopez P, et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up. Eur J Clin Microbiol Infect Dis. 2004;23(12):899–904. doi:10.1007/s10096-004-1249-7.
Singh R, Subba Raju BV, Jain RK, Salotra P. Potential of direct agglutination test based on promastigote and amastigote antigens for serodiagnosis of post-kala-azar dermal leishmaniasis. Clin Diagn Lab Immunol. 2005;12(10):1191–4. doi:10.1128/CDLI.12.10.1191-1194.2005.
Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol. 2001;39(3):849–54. doi:10.1128/JCM.39.3.849-854.2001.
Verma S, Bhandari V, Avishek K, Ramesh V, Salotra P. Reliable diagnosis of post-kala-azar dermal leishmaniasis (PKDL) using slit aspirate specimen to avoid invasive sampling procedures. Trop Med Int Health. 2013;18(3):268–75. doi:10.1111/tmi.12047.
Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P. Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. Diagn Microbiol Infect Dis. 2013;75(4):390–5. doi:10.1016/j.diagmicrobio.2013.01.011.
Roustan G, Jiménez JA, Gutiérrez-Solar B, Gallego JL, Alvar J, Patrón M. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B. Br J Dermatol. 1998;138(3):526–8.
El Hassan AM, Ghalib HW, Zijlstra EE, et al. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans R Soc Trop Med Hyg. 1992;86(3):245–8.
Ismail A, Kharazmi A, Permin H, el Hassan AM. Detection and characterization of leishmania in tissues of patients with post kala-azar dermal leishmaniasis using a specific monoclonal antibody. Trans R Soc Trop Med Hyg. 1997;91(3):283–5.
Musa AM, Khalil EAG, Mahgoub FAE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg. 2008;102(1):58–63. doi:10.1016/j.trstmh.2007.08.006.
Dey A, Singh S. Genetic heterogeneity among visceral and post-kala-azar dermal leishmaniasis strains from eastern India. Infect Genet Evol. 2007;7(2):219–22. doi:10.1016/j.meegid.2006.09.001.
Subba Raju BV, Singh R, Sreenivas G, Singh S, Salotra P. Genetic fingerprinting and identification of differentially expressed genes in isolates of Leishmania donovani from Indian patients of post-kala-azar dermal leishmaniasis. Parasitology. 2008;135(Pt 1):23–32. doi:10.1017/S0031182007003484.
Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P. Genetic typing reveals monomorphism between antimony sensitive and resistant leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India. Parasitol Res. 2012;111(4):1559–68. doi:10.1007/s00436-012-2996-5.
Das VNR, Ranjan A, Pandey K, et al. Short report: clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India. Am J Trop Med Hyg. 2012;86(6):959–61. doi:10.4269/ajtmh.2012.11-0467.
Croft SL. PKDL—a drug related phenomenon? Indian J Med Res. 2008;128(1):10–1.
Thakur CP, Kumar A, Mitra G, et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res. 2008;128(1):38–44.
Das VNR, Pandey K, Verma N, et al. Short report: development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am J Trop Med Hyg. 2009;80(3):336–8.
Elshafie AI, Ahlin E, Mathsson L, ElGhazali G, Rönnelid J. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. J Immunol. 2007;178(8):5383–9.
Saha S, Mondal S, Ravindran R, et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol. 2007;179(8):5592–603.
Rathi SK, Pandhi RK, Chopra P, Khanna N. Lesional T-cell subset in post-kala-azar dermal leishmaniasis. Int J Dermatol. 2005;44(1):12–3. doi:10.1111/j.1365-4632.2004.01579.x.
Ganguly S, Das NK, Panja M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis. 2008;197(12):1762–71. doi:10.1086/588387.
Ganguly S, Mukhopadhyay D, Das NK, et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. J Invest Dermatol. 2010;130(4):1013–22. doi:10.1038/jid.2009.393.
Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis. 2011;5(5):e1171. doi:10.1371/journal.pntd.0001171.
Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis. 2006;194(7):958–65. doi:10.1086/506624.
Ansari NA, Katara GK, Ramesh V, Salotra P. Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis. Clin Exp Immunol. 2008;154(3):391–8. doi:10.1111/j.1365-2249.2008.03761.x.
Salih MA, Ibrahim ME, Blackwell JM, et al. IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan. Genes Immunol. 2007;8(1):75–8. doi:10.1038/sj.gene.6364353.
Katara GK, Ansari NA, Singh A, Ramesh V, Salotra P. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL). PLoS Negl Trop Dis. 2012;6(6):e1703. doi:10.1371/journal.pntd.0001703.
World Health Organization. Control of the leishmaniases. World Health Organ. Tech Rep Ser. 2010;(949):xii–xiii, 1–186, back cover.
Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. World Health Organ. 1992;70(3):341–6.
Dye C, Wolpert DM. Earthquakes, influenza and cycles of Indian kala-azar. Trans R Soc Trop Med Hyg. 1988;82(6):843–50.
Das VNR, Siddiqui NA., Verma RB, et al. Asymptomatic infection of visceral leishmaniasis in hyperendemic areas of Vaishali district, Bihar, India: A challenge to kala-azar elimination programmes. Trans R Soc Trop Med Hyg. 2011;105(11):661–666. doi:10.1016/j.trstmh.2011.08.005.
Ostyn B, Gidwani K, Khanal B, et al. Incidence of symptomatic and asymptomatic leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis. 2011;5(10). doi:10.1371/journal.pntd.0001284.
Stauch A, Sarkar RR, Picado A, et al. Visceral leishmaniasis in the indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis. 2011;5(11). doi:10.1371/journal.pntd.0001405.
Sharma MC, Gupta AK, Das VNR, et al. Leishmania donovani in blood smears of asymptomatic persons. Acta Trop. 2000;76(2):195–6. doi:10.1016/S0001-706X(00)00068-1.
Topno RK, Das VNR, Ranjan A, et al. Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in Bihar, India. Am J Trop Med Hyg. 2010;83:502–6. doi:10.4269/ajtmh.2010.09-0345.
Sudarshan M, Singh T, Singh AK, et al. Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. PLoS Negl Trop Dis. 2014;8(12):e3366. doi:10.1371/journal.pntd.0003366.
Munro DD, Du Vivier A, Jopling WH. Post kala-azar dermal leishmaniasis. Br J Dermatol. 1972;87(4):374–8.
Ono H, Ghoreishi M, Yokozeki H, Katayama I, Nishioka K. A case of post-kala-azar dermal leishmaniasis. J Dermatol. 1998;25(2):118–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing
About this chapter
Cite this chapter
Salotra, P., Kaushal, H., Ramesh, V. (2016). Containing Post Kala-Azar Dermal Leishmaniasis (PKDL): Pre-requisite for Sustainable Elimination of Visceral Leishmaniasis (VL) from South Asia. In: Noiri, E., Jha, T. (eds) Kala Azar in South Asia. Springer, Cham. https://doi.org/10.1007/978-3-319-47101-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-47101-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43611-1
Online ISBN: 978-3-319-47101-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)